
Cytokinetics ends FORTITUDE-ALS trial enrolment
Cytokinetics has completed patient enrolment in the FORTITUDE-ALS trial, a Phase ll clinical study of reldesemtiv (formerly CK-2127107) for the…
Cytokinetics has completed patient enrolment in the FORTITUDE-ALS trial, a Phase ll clinical study of reldesemtiv (formerly CK-2127107) for the…
Thank you for subscribing to Clinical Trials Arena